Inhibiting HRH1 in basal and human EGFR 2 (HER2)-targeted therapy-resistant breast cancer cells can inhibit proliferation, activate mitochondrial apoptotic pathways, and enhance the effectiveness of HER2-targeted therapy [19]. This evidence concerns the gene ERBB2 and breast carcinoma.